Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Where Could The Next Priority Review Voucher Come From?

Executive Summary

There are 21 indications on the list of neglected tropical diseases that qualify for an FDA priority review voucher – an incentive to spur research in those areas – but there aren’t that many drugs in development.

You may also be interested in...



Sanofi Diabetes Franchise Could Get Boost From Retrophin’s Voucher

Priority review ticket might be used on Type 2 diabetes combo LixiLan, expected to be filed later this year.

How Much Is A Priority Review Worth? $67.5 Million, Sanofi/Regeneron Say

Companies’ decision to purchase and redeem BioMarin’s priority review voucher for their PCSK9 inhibitor alirocumab sets the first public benchmark for a voucher’s value and shows the potential advantages to be gained for sponsors in a race to market.

FDA Publishes Raft Of Guidances To Promote Competition

The US FDA has published a raft of guidances on ANDA submissions and labeling updates as well as information requests and discipline review letters.

Topics

Related Companies

UsernamePublicRestriction

Register

PS057102

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel